Humic Based Biostimulants Global Market Report 2023 – By Type (Fulvic Acid, Humic Acid, Potassium Humate), By Type Of Formulation (Liquid, Water-Soluble Granules, Water-Soluble Powders), By Mode of Application (Agriculture, Cereals, Fiber Crops, Fruits and Vegetables, Oilseeds), By End-User (Farmers, Related Industries, Research Institutes) – Market Size, Trends, And Global Forecast 2023-2032

Biostimulants are substances or microorganisms that enhance plant growth when applied in small amounts by increasing the nutrient absorbency rate of plants without any adverse effect on the plants. It improves plant tolerance to biotic stress while also increasing crop productivity. The chemical origin of biostimulants includes natural and biosynthetic biostimulants. Biosynthetic biostimulants are defined as the microorganisms that are applied to plants for the purpose of enhancing their abiotic stress tolerance, nutrition efficiency, and quality traits. The main active ingredients of biostimulants are humic acid, fulvic acid, amino acids, protein hydrolysates, seaweed extracts, and other active ingredients. The various applications of biostimulants are foliar, soil, seed, and other applications. The global biostimulants market is segmented - 1) By Chemical Origin: Natural, Biosynthetic Biostimulants 2) By Active Ingredient: Humic Acid, Fulvic Acid, Amino Acids, Protein Hydrolysates, Seaweed Extracts, Other Active Ingredients 3) By Application: Foliar, Soil, Seed, Other Applications The biostimulants market size will grow from $2.79 billion in 2022 to $3.01 billion in 2023 at a compound annual growth rate (CAGR) of 8.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of biostimulants is expected to grow from $4.09 billion in 2027 at a CAGR of 8.0%. The growth of sustainable agriculture is expected to drive the growth of the biostimulant market. There is an increased focus on sustainable agriculture due to deteriorating factors such as soil degradation, water scarcity, climate change, and also the burden of producing high crop yields to meet the demand. In sustainable agriculture, the use of artificial products like fertilizers and pesticides is prohibited since it degrades soil and harms the environment. Biostimulants, on the other hand, increase the simulation power of the plants to absorb nutrients and help in handling biotic stress. For instance, the United Nations' sustainable development goals for 2030 have a special focus on sustainable agriculture. The use of biostimulants to grow crops free of pesticides and fertilizers also helps in growing crops under unusual conditions. The use of biostimulants helps grow various crops under stress conditions, supporting sustainable agriculture and thereby driving the biostimulant market. Major players in the biostimulants market are BASF, Bayer CropScience, Novozymes A/S, Koppert Biological Systems, Verdesian Life Sciences, Lallemand Plant Care, Valagro, Syngenta, West Coast Marine Bio-Processing Corp., and Italpollina S.p.A. Uncertainty about the legal framework for biostimulants is expected to hinder the biostimulant industry report. Documentation on the labelling and efficacy of biostimulants is not available, and definitions of biostimulants are different worldwide. For instance, the US and Europe lack a specific biostimulant regulatory framework. The Europe has published the new European Fertilizer Regulation (EC) No. 2019/1009 that includes a biostimulants definition and a regulatory path for registrations of such products across the EU states. Moreover, the EU regulation is expected to become effective in 2022 and new standards for processes and methods are expected to be developed in the next few years. Thus, an uncertain legal framework hinders the biostimulant industry. Companies in the biostimulant market are coming up with innovative products to meet the demand and requirements of the customers and have an edge over their competitors. Mostly, start-ups are entering the market with new products. For example, in June 2022, a Spanish provider of biostimulation and sustainable crop nutrition introduced Biimore, an innovative biostimulant globally. It is made from specific and sustainable plant fermentation process from a combination of L-a amino acids, vitamins, sugars and traces of other natural compounds that are not found in any other biostimulant on the market. It improves yield and harvest quality parameters at ultra-low doses. In addition, in September 2022, Evonik Industries, a German specialty chemicals company commenced the development of an innovative biostimulant that reduces fertilizer use by half and keeps 93% of the yields. This is expected to be launched during 2025-2027. In November 2022, J.M. Huber Corporation, a US-based chemical manufacturing company acquired Biolchim Group for an undisclosed sum. The acquisition reinforces Huber's vision of becoming the world's leading provider of sustainable, high-performance agricultural products. Biolchim Group is an Italian manufacturer of a complete range of specialty plant nutrition and biostimulants. Asia-Pacific was the largest region in the biostimulants market in 2022. North America was the second-largest region in the global biostimulants market share. The regions covered in the biostimulants market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the biostimulants market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The biostimulants market consists of the sales of plant extract, inorganic compound, chitosan and other biopolymer, and beneficial microbe biostimulants. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The biostimulants market research report is one of a series of new reports from The Business Research Company that provides biostimulant market statistics, including biostimulant industry global market size, regional shares, competitors with a biostimulant market share, detailed biostimulant market segments, market trends and opportunities, and any further data you may need to thrive in the biostimulant industry. This biostimulants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Agroscience refers to disciplines pertaining to the production and processing of food and fibre, including agronomy, soil science, horticulture, and the study of scientific crop production systems. It refers to the sciences that deal with the processing and production of food and fibre. They cover techniques for cultivating soil, growing and harvesting crops, raising animals, and preparing plant and animal products for use and consumption by humans. The main types of agroscience are biopesticides, biostimulants, and GM seeds. The biopesticide market consists of sales of biopesticide products by entities (organizations, sole traders, and partnerships) that refer to certain types of pesticides derived from natural materials such as animals, plants, bacteria, and certain minerals. They are sourced from acid-based biostimulants and extract-based biostimulants and are used in crops, food, and vegetable applications. The global agroscience market is segmented – 1) By Product: Biopesticides, Biostimulants, GM Seeds 2) By Active Ingredient: Acid-based biostimulants, Extract-based biostimulants 3) By Application: Crops, Food & Vegetable The global agroscience market size will grow from $218.27 billion in 2022 to $235.67 billion in 2023 at a compound annual growth rate (CAGR) of 8.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The agroscience market size is expected to grow to $287.76 billion in 2027 at a CAGR of 5.1%. The growing adoption of sustainable agriculture is expected to propel the growth of the agroscience market. Agricultural communities across the globe are shifting towards sustainable agricultural practices to preserve and restore critical habitats, help protect watersheds, and improve soil health and water quality. For instance, in October 2021, the Agoro Carbon Alliance, the first sustainable agriculture programme backed by Yara, one of the global agriculture leaders in crop nutrition, was launched in India. The Agoro Carbon Alliance aims to create a more sustainable and profitable food future. Therefore, the growing adoption of sustainable agriculture is driving the growth of the agroscience market. Major players in the agroscience market are Agrinos Inc., Nutrien, Arysta LifeScience Corporation (United Phosphorus Ltd.), BASF, Corteva Agriscience, Novozymes (Novo A/S), BioWorks, Dow AgroSciences, DuPont, Biostadt, Koppert, Nufarm, Valent BioSciences, Valagro, AgBiTech, SRT Agro Science Pvt. Ltd., GNP AGROSCIENCES PVT. Ltd., Himalaya Agro Science, Green Earth Agro Science, Sigma Agriscience, Eurofins Scientific, and Arysta LifeScience. Strategic partnerships and collaborations are a key trend gaining popularity in the agroscience market. The key players in the market are expanding their research and development activities through strategic collaborations and partnerships with relevant players in the market. For instance, in April 2021, Corteva Agriscience, a US-based agricultural chemical and seed company, collaborated with a US-based biotechnology company, Ginkgo Bioworks. As part of the collaboration, Ginkgo's cell engineering platform and DNA codebase are being combined with Corteva's natural product development and agricultural expertise to explore the next generation of organically inspired sustainable solutions. In October 2020, American Vanguard, an American producer of agrochemicals and pesticide delivery systems, acquired Agrinos, a US-based biological crop input supplier and developer of biological crop input technologies, for an undisclosed amount. Through the acquisition, American Vanguard is aiming to capitalise on the strong market demand for sustainable crop production as well as the Agrinos portfolio will complement American Vanguard's Green Plant liquid nutrition products, which have enjoyed successful growth in the Central American market. North America was the largest region in the agroscience market in 2022. North America is expected to be the largest market in agroscience market. The regions covered in the agroscience market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the agroscience market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The agroscience market includes revenues earned by entities by soil cultivation, crop cultivation and harvesting, and animal production. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced.It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The agroscience market research report is one of a series of new reports from The Business Research Company that provides agroscience market statistics, including agroscience industry global market size, regional shares, competitors with market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the agroscience industry. This agroscience market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The agricultural biologicals are used to safeguard plants against pests, improve yield and prevent diseases. Agricultural biologicals refer to microorganisms or biochemical derived from naturally occurring microorganisms, plant extracts, insects, or other organic matter. It is combined with synthetic crop protection products as an integrated management solution. Agricultural biologics aims to provide a holistic approach for growers to maximize crop yields, improve quality, and minimize pest resistance. The main types of agricultural biologicals are biopesticides, biofertilizers, and biostimulants. Biopesticides are biological pesticides that are derived from biological materials such as plants, animals, bacteria, and certain minerals. These are derived from microbials, macrobials, biochemicals, other sources and applied by foliar spray, soil treatment, seed treatment, and post-harvest mode of application. The various applications include cereals and grains, oilseed and pulses, fruits and vegetables, turf and ornamentals, and other applications. The global agricultural biologics market is segmented – 1) By Type: Biopesticides, Biofertilizers, Biostimulants 2) By Source: Microbials, Macrobials, Biochemicals, Other Sources 3) By Mode of Application: Foliar Spray, Soil Treatment, Seed Treatment, Post-Harvest 4) By Application: Cereals And Grains, Oilseed And Pulses, Fruits And Vegetables, Turf And Ornamentals, Other Applications The global agricultural biologics market size grew from $10.52 billion in 2022 to $12.11 billion in 2023 at a compound annual growth rate (CAGR) of 15.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services, and affecting many markets across the globe. The market size of global agricultural biologics is expected to grow to $21.07 billion in 2027 at a CAGR of 14.8%. The increasing incidences of pest outbreaks contributed to the growth of the agricultural biologics market. Pest outbreaks refer to an increasing sporadic and large population of pests that are economically harmful to crops and human beings. Due to pest outbreaks, the threats to crops cause 10–40% losses to major food crops such as corn, wheat, and rice cost to the global economy. The pests cause damage to crops and significantly impair growers' productivity and destroy cropland. For instance, in August 2020, an article published by BBC, a UK based broadcasting company included a locust invasion that swept over farms in rural Kenya, Ethiopia, Uganda, Somalia, Eritrea, India, Pakistan, Iran, Yemen, Oman, and Saudi Arabia which estimated a loss of $2.5 billion in crop damage. Hence, increasing pest outbreaks is driving the growth of the agriculture biologics market. Major players in the agricultural biologics market are Syngenta AG, The Dow Chemical Company, Bayer AG, BASF SE, Isagro Company, Marrone Bio Innovations, Koppert Biological Systems, Novozymes A/S, Gowan Company LLC, Vegalab SA, Lallemand Inc., Valent Bioscience, T Stanes & Co Limited, Arysta LifeScience, and Camson Bio Technologies. Strategic collaboration and partnerships are the key trends gaining popularity in the agriculture biologics market. Strategic collaboration is increasingly being done among market players to develop and commercialize agricultural biological products for the betterment of growers and each other businesses. For instance, In October 2021, UPL, an Indian manufacturer, and distributor of bio-solutions announced the collaboration with Chr. Hansen, a Denmark-based bioscience company helps farmers worldwide to fight pest diseases and improve crop quality and yields. Furthermore, in August 2021, Marrone Bio Innovations Inc., a US-based provider of sustainable protection and plant health solutions announced the collaboration with Terramera, a Canada-based agri-tech company to exchange their technological and biological expertise to increase the performance of MBI's crop protection products and accelerate product development. In October 2020, Syngenta Group, a Switzerland-based agrichemical company acquired Valagro for an undisclosed amount. With this acquisition, Syngenta Crop will provide farmers with the more complimentary product and technology choices and underpins its determination to make agriculture more resilient and sustainable. Valagro is a US-based biological company and a producer of innovative agricultural biologicals. North America was the largest region in the agricultural biologics market in 2022. Asia-Pacific is expected to be the fastest-growing region in the agricultural biologics market. The regions covered in the agricultural biologics market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the agricultural biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The agricultural biologics market consists of sales of agricultural biologicals from sources such as plant extracts and minerals. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The agricultural biologics market research report is one of a series of new reports from The Business Research Company that provides agricultural biologics market statistics, including agricultural biologics industry global market size, regional shares, competitors with an agricultural biologics market share, detailed agricultural biologics market segments, market trends and opportunities, and any further data you may need to thrive in the agricultural biologics industry. This agricultural biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cell culture is a process for developing substrates for the safe production of viral vaccines. 3D cell culture is an in vitro technique wherein the cells can grow in an artificially created environment. The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The main types of 3D cell culture technologies are scaffold-based, scaffold-free, and 3D bioreactors. The 3D bioreactors are small plastic cylinder chambers designed specifically for growing cells in three dimensions. The various scaffold-based technologies include hydrogels, polymeric scaffolds, micropatterned surface microplates and the different scaffold-free technologies are hanging drop microplates, spheroid microplates, microfluidic 3d cell culture, magnetic levitation and 3D bioprinting. The technologies are applied for cancer research, stem cell research, drug discovery, and regenerative medicine that are used by research laboratories and institutes, biotechnology and pharmaceutical companies, hospitals and diagnostic centers, and other end users. The global 3D cell culture technologies market is segmented – 1) By Type: Scaffold-based, Scaffold-free, 3D Bioreactors 2) By End Users: Research Laboratories and Institutes, Biotechnology and Pharmaceutical Companies, Hospitals and Diagnostic Centers, Other End Users 3) By Scaffold-based: Hydrogels, Polymeric scaffolds, Micropatterned Surface Microplates 4) By Scaffold-free: Hanging Drop Microplates, Spheroid Microplates, Microfluidic 3D Cell Culture, Magnetic Levitations & 3D Bioprinting 5) By Application: Cancer Research, Stem Cell Research, Drug Discovery, Regenerative Medicine The global 3d cell culture technologies market size grew from $2.39 billion in 2022 to $2.83 billion in 2023 at a compound annual growth rate (CAGR) of 18.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the 3d cell culture technologies market is expected to grow from $5.65 billion in 2027 at a CAGR of 18.9%. The increasing requirement for organ transplantation is driving the 3D Cell Culture Technologies Market. 3D cell culture helps in forming a three-dimensional structure which further helps in mimicking the tissue or organ and therefore helps in organ transplantation. 3D cell structures are capable of tissue and organ regeneration as well as providing the provision for drug toxicology screening. For instance, according to the Organ Procurement and Transplantation network, an American non-profit organization administering the organ transplantation in the US, 41,354 organ transplantations were performed in the United States in 2021 which was an increase of 5.9% as compared to 2020 and the number exceeded 40,000 mark for the first time ever. Major players in the 3D cell culture technologies market are Becton Dickinson, Corning Incorporation, Eppendorf, GE Healthcare, Merck KGaA, Thermo Fisher Scientific, Lonza, HiMedia Laboratories, Agilent Technologies, PromoCell GmbH, CellGenix GmbH, InvivoGen, Greiner Bio-One, Irvine Scientific, Cell Culture Company (CCC) LLC., Sera Care Life Sciences Incorporation, American Type Culture Collection, Miltenyi Biotec, AITbiotech, ESSEN, Sigma-Aldrich, Bel-Art, MilliporeSigma, Cellgenix, Sumitomo Bakelite, EMD Millipore, AffymetrixInc., VWR International, LLC., WHEATON IndustriesInc., and Sartorius A. The possibility of contaminating the cells is restricting the 3D Cell Culture technologies market. Contamination of the cell culture refers to the presence of bacteria, moulds, yeasts, viruses, and mycoplasma that can adversely affect the cell culture. Contamination usually occurs when the cells are mishandled or due to the lack of adequate care, as a result the process of regeneration may get affected. According to a study conducted by Yale and Tuff's university, it was found that 3D cultures are more complex than 2D cell cultures and they require a more controlled cellular environment in order to mimic structures for tissue or organ transplants. Therefore, probability of cell culture contamination is relatively higher in 3D cell cultures. Implementing the latest technology is the latest trend in the 3D Cell culture market. For example, various companies have adopted one such advancement in the market for 3D cell culture, this is the use of the vivo/vitro environment. Cell expansion and interactions under 2D are not appropriate in vitro models but when compared with 3D cell culture technique, it offers a better cell culture environment. The Vitro environment enables researchers or doctors to conduct the procedure in a controlled environment outside the organism. This procedure is gaining importance as it plays a vital role in monitoring the health of patients. FDA approved Biotek's 3D cell expansion system to be used as a medical device. It also approved Biotek's Polycaprolactone (PCL) which is a biodegradable polyester material that is used in many FDA-approved implants and drug delivery devices. FDA regulates the cell culture technologies under title 21, sec 864.2240. FDA states that cell and tissue culture technologies should be labelled or mentioned as sterile, or else they would be removed from the good manufacturing practice of the quality system. Each technology unit should maintain procedures to receive, review, and evaluate complaints. These procedures should also include consistent documentation of the receipts. In May 2021, CELLINK Group, a USA-based start-up that designs and supplies technologies and services to enhance biology research, has acquired Visikol Corporation for $7.5 million. With this acquisition, CELLINK made an entrance into the contract research market. Visikol Corp., an American contract research services company that provides pharma and biotech industries with leading services in 3D cell culture, 3D tissue imaging, multiplex imaging, and digital pathology. North America was the largest region in the 3D cell culture technologies market in 2022. Western Europe was the second largest region in the 3D cell culture technologies market share. The regions covered in the global 3D cell culture technologies market report analysis are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the 3D cell culture technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The 3D cell culture technologies market consists of sales of 3D cell culture technologies such as microfluidics, hydrogels scaffolds, scaffold-free 3D cell culture techniques, spheroids, cube, spherical droplet, stacked plate, magnetic bead, organ-on-chips and other technologies. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The 3D cell culture technologies market research report is one of a series of new reports from The Business Research Company that provides 3D cell culture technologies market statistics, including 3D cell culture technologies industry global market size, regional shares, competitors with a 3D cell culture technologies market share, detailed 3D cell culture technologies market segments, market trends and opportunities, and any further data you may need to thrive in the 3D cell culture technologies industry. This 3D cell culture technologies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cell culture consumables and equipment are designed to aid scientists in growing new cells in the culture media for drug development, tissue culture, engineering, gene therapy, vaccine production, and toxicity testing. The main products in cell culture consumables and equipment are consumables and instruments. The cell culture instruments involve the various instruments that are required for cell culture in the cell culture laboratory. The various instruments used in cell culture are cell culture vessels, bioreactors, biosafety cabinets, carbon dioxide incubators, and centrifuge and consumables are media, sera, and reagents. The applications involved are vaccination, toxicity testing, cancer research, drug screening and development, recombinant products, stem cell technology, regenerative medicine, and others that are used by end-users such as industrial, biotechnology, agriculture, and others. The global is segmented - 1) By Product: Consumables, Instruments 2) By End User: Industrial, Biotechnology, Agriculture, Other End Users 3) By Application: Vaccination, Toxicity testing, Cancer Research, Drug Screening and Development, Recombinant Products, Stem cell technology, Regenerative Medicine, Other End Users 4) By Consumables: Media, Sera, Reagents 5) By Instruments: Cell Culture Vessels, Bioreactors, Biosafety Cabinets, Carbon Dioxide Incubators, Centrifuges The global cell culture consumables and equipment market grew from $10.99 billion in 2022 to $12.12 billion in 2023 at a compound annual growth rate (CAGR) of 10.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the cell culture consumables and equipment is expected to grow from $17.98 billion in 2027 at a CAGR of 10.4%. An increase in the prevalence of chronic diseases is driving the growth of the cell culture consumables and equipment market. Chronic diseases such as cancer, diabetes, heart diseases, obesity, and hypertension are growing rapidly. A few chronic diseases are caused due to loss or damage of certain types of cells. Such diseases can be cured by replacing the destroyed cells with new ones that are produced by pluripotent stem cells, using cell culture consumables and equipment. So, with the rising incidence of chronic diseases, there is an increased need for such equipment that can produce new cells outside the natural environment, thus driving the growth of this market. For example, according to the World Health Organization, chronic disease prevalence is expected to rise by 57% by the year 2020. Major players in the cell culture consumables and equipment market are Becton Dickinson, Corning Incorporation, Eppendorf, GE Healthcare, Merck KGaA, Thermo Fisher Scientific, Lonza, HiMedia Laboratories, Agilent Technologies, and PromoCell GmbH. Contamination of cell culture is the most prominent factor restricting the growth of cell culture consumables and equipment market. Contaminated culture is the presence of non-living substances or unwanted foreign microorganisms that have undesirable effects on the cell culture. Using contaminated culture cells has several negative consequences on the users and thus hampers the growth of this market. For example, an article published on MedCrave, stated that Mycoplasma is one of the most common and difficult to detect contaminants. The article also highlighted the results of a study on fibroblasts and keratinocyte cell lines that showed 32.35% of contamination, out of which 17.65% were mycoplasma contaminated cultures, followed by fungal (8.82%) and bacterial (5.88%) contaminants. Hence, the high risk associated with cell culture techniques poses a threat to the growth of the cell culture consumables and equipment market. Companies in cell culture consumables and equipment are investing more in 3D cell culture for its new and advantageous features. 3D cell culture may be defined as the culture of living cells within micro-assembled devices and supports that present a three-dimensional structure and are used to replicate a tissue or an organ in an artificial environment by allowing the cells to interact with the surroundings in all three directions. 3D cell cultures are more relevant with a higher degree of structural complexity and maintain the steady-state for more time as compared to 2D cell cultures. In August 2021, Amerigo Scientific, a US-based manufacturer of biomedical and life sciences products, launched #D cell cultures for research purposes. FDA regulates cell culture consumables and equipment in the U.S. Under title 21, Sec 864.2240. For cell and tissue culture equipment, the FDA states that if the equipment is not labelled or mentioned as sterile, it would be removed from the good manufacturing practises of the quality system. Additionally, each manufacturing unit should maintain procedures to receive, review, and evaluate complaints. These procedures require consistency and punctuality, along with the documentation of the receipts. Therefore, these regulatory standards improve the safety and efficacy of instruments and consumables used during cell culture processes. In July 2021, Sartorius, a Germany-based laboratory instrument manufacturer, acquired Xell AG for an undisclosed amount. The acquisition would expand Sartorius’ current media offering and other cell culture products. Xell AG is a Germany-based cell culture specialist. North America was the largest region in the cell culture consumables and equipment market in 2022. Western Europe was the second largest region in the global cell culture consumables and equipment market share. The regions covered in the global cell culture consumables and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cell culture consumables and equipment market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The cell culture consumables and equipment market consists of sales of flasks, tubes, dishes or cryovials, serological pipettes or centrifugation tubes, bottles, cell scrapers, strainers, coverslips, and inserts. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The cell culture consumables and equipment market research report is one of a series of new reports from The Business Research Company that provides cell culture consumables and equipment market statistics, including cell culture consumables and equipment industry global market size, regional shares, competitors with a cell culture consumables and equipment market share, detailed cell culture consumables and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the cell culture consumables and equipment industry. This cell culture consumables and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pharmaceutical active pharmaceutical ingredients (API) manufacturing refers to the production of the active substances that give a pharmaceutical medicine its desired impact on the body to treat a condition. Chemical components must be processed in order to make APIs. A biologic drug's active component is referred to as a bulk process intermediate. The main therapy areas of pharmaceutical API manufacturing are cardiovascular disorders, metabolic disorders, neurological disorders, oncology, musculoskeletal disorders, NSAIDs, and other therapeutics uses. Cardiovascular diseases are a group of heart and blood vessel disorders. The various API type include chemical API and biological API that are used to produce innovative drugs, generic prescription drugs, and over-the-counter (OTC) drugs. The global pharmaceutical api manufacturing market is segmented - 1) By Therapy Area: Cardiovascular disorders, Metabolic disorders, Neurological disorders, Oncology, Musculoskeletal disorders, NSAIDs, Other therapeutics uses 2) By API Type: Chemical API, Biological API 3) By Drug Type: Innovative Drugs, Generic Prescription, Over-the-counter (OTC) Drugs The global pharmaceutical api manufacturing market size grew from $195.29 billion in 2022 to $209.93 billion in 2023 at a compound annual growth rate (CAGR) of 7.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global pharmaceutical api manufacturing is expected to grow from $266.72 billion in 2027 at a CAGR of 6.2%. The rise in the aging population is one of the major drivers of the pharmaceutical API manufacturing market. As the aging population increases, the demand for pharmaceutical drugs also increases. API acts as a specialty drug in these medicines to cure a particular disease. For instance, in October 2022, according to an article shared by WHO, a Switzerland-based specialized agency of the United Nations responsible for international public health, 80% of senior citizens will reside in low- and middle-income nations by 2050. The population is aging considerably more quickly than in the past. In 2020, there will be more persons over the age of 60 than under five-year-olds. Therefore, rise in aging population is driving the growth of the pharmaceutical API manufacturing market. Major players in the pharmaceutical API manufacturing market report are Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim, PfizerInc., Aurobindo Pharma, Novartis AG, Dr. Reddy's Laboratories, Merck & Co.Inc., BASF SE., Bayer Healthcare, Mylan N.V., Albemarle Corporation, Actavis PLC., Hospira Inc., Ranbaxy Laboratories, Virbac, Zoetis, Heska Co., AbbVie Inc., AstraZeneca PLC., Eli Lilly and Company, GlaxoSmithKline PLC., Sanofi, Bristol-Myers Squibb, CiplaInc., and F. Hoffmann-La Roche Ltd. Stringent regulations for approval of pharmaceutical drugs act as a restraint on the pharmaceutical API manufacturing market. Various regions have their own set of rules, guidelines, and regulations set by their respective drug regulatory bodies. For example, in Japan, the manufacturers have to register an API with Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) through the country’s Drug Master File (DMF) system. Products like APIs and new excipients i.e. inactive substances used in a drug should be registered compulsorily. The API manufacturer is also responsible for DMF registration, even if they don't have their office in Japan. They should appoint an in-country caretaker (ICC) to apply on their behalf. Also, if there are any changes to be made to DMF products, either an application for change in registration or a minor change notification should be submitted by the ICC to the PMDA. This whole process delays the drug approvals, thereby negatively affecting the pharmaceuticals API manufacturing market. Many companies use modern technologies such as process control, and powder handling to optimize API manufacturing. These technologies include advances in Lyophilization i.e. freeze-drying process. It is a low-temperature dehydration process that involves freezing the product, lowering pressure, and then removing the ice formed. For instance, Telstar, a company that manufactures efficient integrated systems for pharmaceutical and manufacturing processes, developed LyoGistics Zero, automatic loading and unloading system for freeze dryers to manufacture hazardous products. The system uses a linear magnetic driving mechanism that functions without racks and belts to reduce particle generation and this improves the hygiene in API manufacturing. Also, ILC Dover, a pharmaceutical company, developed the JetBreaker system, a semi-automatic powder handling system that separates powdered media and buffers powders so that they can be mixed better in a solution. In March 2021, Piramal Pharma Ltd., an India-based healthcare solutions company, acquired Hemmo Pharmaceuticals for an amount of $105.8 million. This acquisition is expected to expand PPS’s capacity to provide integrated services to its clients globally by gaining access to the expanding peptide API industry. The deal would also increase peptide API manufacturing and development capabilities. Hemmo Pharmaceuticals is an India-based developer and manufacturer of peptide APIs. North America was the largest region in the pharmaceutical API manufacturing market in 2022. The Middle East is expected to be the fastest growing region in the global pharmaceutical API manufacturing market share during the forecast period. The regions covered in the pharmaceutical API manufacturing industry report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the pharmaceutical API manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The pharmaceutical active pharmaceutical ingredients (API) manufacturing market includes tablet, capsule, cream, and injectable sales.Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The pharmaceutical active pharmaceutical ingredients (API) manufacturing market research report is one of a series of new reports from The Business Research Company that provides pharmaceutical active pharmaceutical ingredients (API) manufacturing market statistics, including pharmaceutical active pharmaceutical ingredients (API) manufacturing industry global market size, regional shares, competitors with a pharmaceutical active pharmaceutical ingredient (API) manufacturing market share, detailed pharmaceutical active pharmaceutical ingredients (API) manufacturing market segments, pharmaceutical active pharmaceutical ingredients (API) manufacturing market trends and opportunities, and any further data you may need to thrive in the pharmaceutical active pharmaceutical ingredients (API) manufacturing industry. The pharmaceutical active pharmaceutical ingredients (API) manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Generic pharmaceuticals refer to a drug that was developed to have the same dosage form, safety, strength, mode of administration, quality, performance attributes, and intended use as an already marketed brand-name drug. The action and clinical benefits of a generic drug are identical to those of a brand-name drug. The three main types of generic pharmaceuticals are biosimilar; simple generic, and super generic. A biosimilar is a biological product that is very similar to a reference biologic and has no clinically significant differences in terms of safety, purity, or potency. The drugs are delivered through oral, injectable, dermal/topical, and inhalers that are used for various therapies such as CNS, cardiovascular, dermatology, genitourinary/hormonal, respiratory, rheumatology, diabetes, and oncology. The various distribution channels involved is hospital pharmacies, retail pharmacies, and online pharmacies. The global generic pharmaceuticals market is segmented - 1) By Therapy: CNS, Cardiovascular, Dermatology, Genitourinary/Harmonal, Respiratory, Rheumatology, Diabetes, Oncology 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By Type: Biosimilar, Simple Generic, Super Generic 4) By Drug Delivery: Oral, Inectables, Dermal/Topical, Inhaler The global generic pharmaceuticals market size grew from $332.43 billion in 2022 to $358.5 billion in 2023 at a compound annual growth rate (CAGR) of 7.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global generic pharmaceuticals is expected to grow from $453.19 billion in 2027 at a CAGR of 6.0%. The rising incidence of chronic diseases is one of the major drivers of the generic pharmaceuticals market. As more individuals are diagnosed with chronic diseases, they look for more medicines for treatment. Branded drugs come at a premium price, while generic drugs are available at a lower cost and have the same chemical composition as branded drugs. The low cost and same chemical composition and strength of generic drugs make a patient buy generic drugs instead of branded drugs. If it is a chronic disease, the treatment goes on for a longer period, and hence, the sales of generic drugs also increase. For instance, according to the WHO (World Health Organization), over the next 10 years, the number of deaths due to chronic disease is projected to increase by 17%. Also, in 2020, almost 3-quarters of all deaths in the world are due to chronic diseases. Major players in the generic pharmaceuticals market are Teva Pharmaceuticals, Mylan NV, Sandoz International GmbH, Hospira (Pfizer Inc.), Sun Pharmaceutical, Lupin Limited, Endo International PLC., Dr Reddy's Laboratories, Apotex Holdings, Fresenius Kabi Ag, Aurbindo Pharma, Aspen Pharmacare, Sanofi, Cipla, Hikma Pharmaceuticals, Stada Arzneimittel, Krka Group, Nichi-Iko Pharmaceutical, Valeant, Zydus Cadila, Merck & Co., Mitsubishi Tanabe Pharma, Momenta Pharmaceuticals, Nexus Pharmaceuticals, Novo Nordisk, Ranbaxy Laboratories Ltd., Sawai Pharmaceuticals, Novartis AG, Pfizer and Johnson & Johnson Services. The lack of awareness about generic drugs is one of the restraints on the generic pharmaceuticals market. The high marketing and advertisement of branded drugs overshadow the availability of generic drugs, which are a substitute for expensive branded drugs. Thus, consumers opt for branded drugs even though the generic drugs carry the same chemical formulation as their counter-branded drugs. According to an article published on CVS HEALTH, many doctors and pharmacists preferred to offer branded drugs to their patients over generic drugs. This prevents the patients to go for generic drugs as they develop a preconceived notion of generic drugs not being on par with branded drugs. For example, according to research conducted by Sahana K Hebbar, in the International Journal of Basic & Clinical Pharmacology, out of 100 patients and 50 non-medical staff, 95% of the patients and 60% of the non-medical staff didn't know about generic drugs. Thus, a lack of awareness about the availability of generic drugs hampers the generic pharmaceuticals market. 3D printing technology can transform the manufacturing of drugs in the generic pharmaceuticals market. 3D printed pharmaceuticals help improve R&D productivity and deliver new benefits to patients. 3D printing allows the manufacturer to produce drugs with customised size, shape, and texture, which is not possible in traditional manufacturing of generic drugs. 3D printing can help the manufacturer to make generic drugs that have different release dates, appearances, and tastes. For example, GlaxoSmithKline (GSK) completed a study where ultraviolet (UV) and 3D printing were used to manufacture tablets to treat Parkinson's disease. Martin Wallace, director of GSK Technology, said that GSK is investing in 3D printing to manufacture pills and tablets. Also, Aprecia pharmaceutical company launched 'ZipDose' technology, which manufactures 3D printed drugs. Drug manufacturers must comply with the CGMP (Current Good Manufacturing Practice) regulations that come under the US Food and Drug Administration (FDA) which includes generic pharmaceuticals. The CGMP regulations require manufacturers to maintain a minimum quality standard for the methods, controls, and facilities used in the manufacturing, packaging, and processing of drug products. Part- 99 of chapter 1 under title 21-Food And Drugs of CFR (Code of Federal Regulations) contains subparts from A to H. The whole part-99 describes the guidelines that need to be followed by drug manufacturers regarding the dissemination of information on human drugs, including biologics, and devices. The guidelines concern the safety, effectiveness, or benefit of use that is not included in the approved labelling for a drug or device approved by the Food and Drug Administration for marketing. The guidelines regulate the information regarding the drugs that should be delivered to the health care practitioner, pharmacy benefit manager, health insurance issuer, group health plan, or federal or state government agency. In January 2020, ANI Pharmaceuticals, Inc., a USA-based integrated specialty pharmaceutical company focused on developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceuticals, acquired Commercial and Pipeline Generic Products from American Pharmaceuticals, Ltd. for $52.5M in cash. This acquisition substantially increases ANI Pharmaceuticals, Inc.’s commercial portfolio and late-stage generic pipeline. American Pharmaceuticals is a USA-based company focused on the development, manufacture, and sale of high-quality generic pharmaceutical products. North America was the largest region in the generic pharmaceuticals market in 2022. Middle East is expected to be the fastest-growing region in the generic pharmaceuticals market report during the forecast period. The regions covered in the generic pharmaceuticals analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the generic pharmaceuticals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The generic pharmaceuticals market consists of sales of paracetamol, cefixime, amoxicillin, and ofloxacin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The generic pharmaceuticals market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The generic pharmaceuticals market research report is one of a series of new reports from The Business Research Company that provides generic pharmaceuticals market statistics, including generic pharmaceuticals industry global market size, regional shares, competitors with a generic pharmaceuticals market share, detailed generic pharmaceuticals market segments, market trends and opportunities, and any further data you may need to thrive in the generic pharmaceuticals industry. The generic pharmaceuticals market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Biologics Market Definition

The biologics market consists of sales of biologics and related services by entities (organizations, sole traders and partnerships) that produce biologics or biosimilars to treat and prevent various microbial diseases and cancers. The biologics market comprises companies manufacturing biological products that are derived from genetically modified proteins and human genes. Biologics products include a wide range of recombinant therapeutic proteins, gene therapy tissues, somatic cells, vaccines, and allergenics. Biologics products are subjected to various laws and regulations that deal with patenting, testing, safety, efficacy, and marketing. Biologics products are isolated from natural sources such as human, animal, and microorganisms by biotechnological methods and other cutting-edge technologies.